538 related articles for article (PubMed ID: 23341526)
41. Clinical research on stereotactic radiosurgery combined with epithermal growth factor tyrosine kinase inhibitors in the treatment of brain metastasis of non-small cell lung cancer.
Jia F; Cheng X; Zeng H; Miao J; Hou M
J BUON; 2019; 24(2):578-584. PubMed ID: 31128009
[TBL] [Abstract][Full Text] [Related]
42. Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.
Arbour KC; Kris MG; Riely GJ; Ni A; Beal K; Daras M; Hayes SA; Young RJ; Rodriguez CR; Ahn L; Pao W; Yu HA
Cancer; 2018 Jan; 124(1):105-109. PubMed ID: 28940498
[TBL] [Abstract][Full Text] [Related]
43. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis.
Ponce Aix S; Novello S; Garon EB; Nakagawa K; Nadal E; Moro-Sibilot D; Alonso Garcia M; Fabre E; Frimodt-Moller B; Zimmermann AH; Visseren-Grul CM; Reck M;
Cancer Treat Res Commun; 2021; 27():100378. PubMed ID: 33905962
[TBL] [Abstract][Full Text] [Related]
44. Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.
Nonagase Y; Okamoto K; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Shimizu T; Tsurutani J; Nakagawa K
Anticancer Drugs; 2016 Mar; 27(3):251-3. PubMed ID: 26575001
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Ready N
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
[TBL] [Abstract][Full Text] [Related]
46. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;
Lancet Oncol; 2019 Dec; 20(12):1655-1669. PubMed ID: 31591063
[TBL] [Abstract][Full Text] [Related]
47. A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer.
Neuhaus T; Ko Y; Muller RP; Grabenbauer GG; Hedde JP; Schueller H; Kocher M; Stier S; Fietkau R
Br J Cancer; 2009 Jan; 100(2):291-7. PubMed ID: 19127261
[TBL] [Abstract][Full Text] [Related]
48. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
Zhang Q; Zhang X; Yan H; Jiang B; Xu C; Yang J; Chen Z; Su J; Wu YL; Zhou Q
Thorac Cancer; 2016 Nov; 7(6):648-654. PubMed ID: 27755835
[TBL] [Abstract][Full Text] [Related]
49. Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.
Miyamoto S; Azuma K; Ishii H; Bessho A; Hosokawa S; Fukamatsu N; Kunitoh H; Ishii M; Tanaka H; Aono H; Nakahara Y; Kusaka K; Hosomi Y; Kikuchi N; Mori Y; Itani H; Hamada A; Yamada K; Okamoto H
JAMA Oncol; 2020 Jul; 6(7):e201250. PubMed ID: 32407455
[TBL] [Abstract][Full Text] [Related]
50. A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911.
Yamada K; Aono H; Hosomi Y; Okamoto H; Kato T; Komase Y; Nishikawa M; Azuma K; Takeoka H; Okuma Y; Nakahara Y; Sato A; Oba MS; Morita S; Kunitoh H; Watanabe K
Eur J Cancer; 2015 Sep; 51(14):1904-10. PubMed ID: 26174465
[TBL] [Abstract][Full Text] [Related]
51. Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan.
Lin CH; Hsu KH; Chang SN; Tsou HK; Sheehan J; Sheu ML; Pan HC
Radiat Oncol; 2015 Jun; 10():127. PubMed ID: 26048754
[TBL] [Abstract][Full Text] [Related]
52. Erlotinib for the treatment of brain metastases in non-small cell lung cancer.
Brower JV; Robins HI
Expert Opin Pharmacother; 2016; 17(7):1013-21. PubMed ID: 26967582
[TBL] [Abstract][Full Text] [Related]
53. The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients.
Bai H; Han B
Am J Clin Oncol; 2013 Apr; 36(2):110-5. PubMed ID: 22391431
[TBL] [Abstract][Full Text] [Related]
54. Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis.
Olmez I; Donahue BR; Butler JS; Huang Y; Rubin P; Xu Y
Lung Cancer; 2010 Nov; 70(2):174-9. PubMed ID: 20207442
[TBL] [Abstract][Full Text] [Related]
55. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
Li J; Qu L; Wei X; Gao H; Wang W; Qin H; Tang C; Guo W; Wang H; Liu X
Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):299-304. PubMed ID: 22613337
[TBL] [Abstract][Full Text] [Related]
56. Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer.
Yang RF; Yu B; Zhang RQ; Wang XH; Li C; Wang P; Zhang Y; Han B; Gao XX; Zhang L; Jiang ZM
Braz J Med Biol Res; 2017 Nov; 51(1):e6073. PubMed ID: 29185589
[TBL] [Abstract][Full Text] [Related]
57. Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis.
Zheng MH; Sun HT; Xu JG; Yang G; Huo LM; Zhang P; Tian JH; Yang KH
Biomed Res Int; 2016; 2016():5807346. PubMed ID: 27006948
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses.
Zhao B; Wang Y; Wang Y; Chen W; Zhou L; Liu PH; Kong Z; Dai C; Wang Y; Ma W
Aging (Albany NY); 2020 Jul; 12(14):14244-14270. PubMed ID: 32669477
[TBL] [Abstract][Full Text] [Related]
59. Phase I/II study of erlotinib plus S-1 for patients with previously treated non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0808/0913.
Nakahara Y; Shimokawa T; Misumi Y; Nogami N; Shinkai T; Seki N; Hosomi Y; Hida N; Okamoto H
Invest New Drugs; 2021 Feb; 39(1):202-209. PubMed ID: 32803700
[TBL] [Abstract][Full Text] [Related]
60. Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer.
Liu K; Jiang G; Zhang A; Li Z; Jia J
BMC Cancer; 2020 Jan; 20(1):76. PubMed ID: 32000711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
